Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

ing of BioMarin's clinical trials of GALNS, Firdapse, PEG-PAL, BMN-673 , BMN-701 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pha
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Research and Markets has ... Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to ... purposes of this report, the human microbiome market is segmented ... microbiome market is expected to be valued as $294 million ... of 22.3% within the forecast period of 2019-2023. The market ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... July 1 Watson Pharmaceuticals, Inc. (NYSE: WPI ... ) have approved the terms and conditions of the previously announced acquisition ... PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia ... , The ...
... SHENZHEN, China , July ... TCM ), a leading specialty,pharmaceutical company focusing on ... in China , today,announced that it filed its Annual ... 2009 with the Securities and Exchange Commission on ...
Cached Medicine Technology:Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets 2Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets 3Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets 4Tongjitang Files 2009 Annual Report on Form 20-F 2
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... California (PRWEB) September 20, 2014 Final ... have announced the release of the Information theme for FCPX ... would use to describe the Information theme,” says Christina Austin, ... easy to look so professional.” , Information features easy to ... the parameters of the environment. Change the background color, color ...
(Date:9/20/2014)... September 20, 2014 MarijuanaDoctors.com recently ... showing at the PAIN Week conference that was ... and Casino in Las Vegas from September 2nd ... attended PAIN Week in the hopes of educating ... viable and legitimate tool to treat chronic Pain, ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing ... among patients with prescription drug coverage, may now be ... report from the Department of Health and Human ... laws prohibit suppliers from offering side-payments to increase sales ... , The report highlights that two recent surveys, including ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- As kids transition ... targets of cyberbullies, according to a recent study. ... 5 through 8 found that verbal and physical bullying ... vary, bullying intervention and prevention strategies must address all ... among boys and girls, the researchers said. The study ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... Safety Initiatives, DUBLIN, Ohio, Dec. 3 ... participating in the Institute for Healthcare,Improvement,s (IHI) 5 ... it is granting $537,000 to 37 hospitals that,enroll ... receive an average of,$15,000 each to help deepen ...
... COMPOUNDERS; ENABLES CONVENIENT, SECURE, VIRTUALLY ... OF CLASS II CONTROLLED SUBSTANCES, LAKE FOREST, ... provider of outsourced hospital compounded sterile preparations,announced a ... entire line of Schedule II Controlled Substances.,The initiative ...
... equipment, survey finds , , MONDAY, Dec. 3 (HealthDay News) -- ... nearest emergency room might want to keep a new finding ... United States have all the equipment they should have on ... to the survey, however, so the UCLA researchers suspect the ...
... income families and,uninsured individuals everywhere now have access ... prescription per month with delivery to their,home or ... new prescription assistance service,to those who qualify. It ... coverage, according to Doug Pierce, founder of the ...
... C-section has hit number one for,inpatient surgery in the ... Scarring, swelling, tenderness and surgical recovery are a,reality for ... Cesarean Underwear(TM) attempts to address the needs,of Cesarean moms ... of a C-section in mind. See http://www.cpanty.com ., ...
... Misys plc (FTSE: MSY.L),the global application software and services ... its Equation and Trade Innovation,solutions to support its expansion ... installed in its Hong Kong location since,2003, and have ... and,business for the bank. UCB concluded to expand the ...
Cached Medicine News:Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 2Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 3Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 4Health News:PharMEDium Announces Electronic 222 Ordering Initiative 2Health News:Most ERs Not Fully Prepared for Pediatric Patients 2Health News:Most ERs Not Fully Prepared for Pediatric Patients 3Health News:$7 Brand Name Prescriptions for Low Income and Un-Insured Avoid Prescription Discount Cards! 2Health News:Finally, Easy After-Cesarean Care for the 1.3 Million C-Section Moms 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 3
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
... Vivid i is the worlds ... high-performance, full-featured imaging in a lightweight design. ... addresses one of the biggest challenges in ... diagnostic information. The new system expands the ...
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... with a diseased heart, the only therapy solution open ... However, donor organs are not always readily available. For ... on the waiting list for a donor organ. , ... the life of a patient. On the one hand, ...
Medicine Products: